Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-053371

Chief Business Development Off sold 6,771 shares at an average $48.57 ($328,837)

  • Chief Business Development Off acquired 6,771 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise +2,604 $6.55 $17,056 2,604 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise +2,605 $6.55 $17,063 5,209 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise +1,562 $7.27 $11,356 6,771 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Sale −5,878 $48.46 $284,848 893 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Sale −893 $49.26 $43,989 0 D
Derivatives
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise · Stock Option (Right to Buy) −2,604 33,855 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise · Stock Option (Right to Buy) −2,605 62,500 D
BENZENO SHARON Chief Business Development Off 2020-10-01 Option exercise · Common Stock (Right to Buy) −1,562 42,188 D
Open-market sales · 6,771 sh · avg $48.57 · $328,837
Loading xslF345X03/doc4.xml…